ArticleTranslational pediatrics2026
Serum HMGB1 as a biomarker and predictive model for pediatric septic shock: a cohort study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis, defined as life-threatening organ dysfunction due to a dysregulated host response to infection, remains a leading cause of pediatric mortality. High mobility group box 1 (HMGB1), a late inflammatory mediator, has shown prognostic value in adult sepsis, but its utility in pediatric populations remains inadequately investigated. This study aimed to evaluate HMGB1 as a prognostic biomarker for septic shock in children with sepsis and to develop a clinical prediction model. Methods: In this prospective cohort study, we enrolled 46 pediatric patients (aged 1 month to 18 years) with sepsis and organ dysfunction at a tertiary hospital in China (March 2022 to December 2023). Serum HMGB1 levels were measured within 24 hours of admission. Patients were stratified into shock (n=17) and non-shock (n=29) groups. Receiver operating characteristic (ROC) curve analysis evaluated the diagnostic performance of HMGB1 and other biomarkers. Multivariable logistic regression identified independent predictors, which were integrated into a nomogram prediction model. Results: Septic shock developed in 17 patients (37.0%). The shock group exhibited significantly elevated levels of HMGB1, procalcitonin (PCT), serum amyloid A (SAA), interleukin-6 (IL-6), fibrin degradation products, and urea (all P<0.05). ROC analysis showed that HMGB1 [area under the curve (AUC) 0.755], PCT (AUC 0.843), IL-6 (AUC 0.738), and SAA (AUC 0.704) predicted shock development. Multivariable analysis identified HMGB1 and PCT as independent risk factors. The nomogram combining these biomarkers achieved excellent discrimination (C-index 0.869, AUC 0.874) with sensitivity of 82.4% and specificity of 89.7%. Conclusions: Serum HMGB1, particularly when combined with PCT in a nomogram model, demonstrates excellent prognostic accuracy for early identification of septic shock risk in pediatric sepsis. This practical bedside tool may facilitate timely risk stratification and guide clinical decision-making, though external validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.